Drug intelligence / Profile preview

paracetamol + piroxicam

Development stage
Unknown
Lead developer
Université de Monastir
Modality
Small Molecules
Administration
Oral
01

Overview

Paracetamol + piroxicam is an investigational combination of the aniline analgesic paracetamol (acetaminophen) and the nonsteroidal anti-inflammatory drug (NSAID) piroxicam. It has been primarily studied by the University of Monastir in Tunisia for the management of acute post-traumatic pain in the extremities. Paracetamol is believed to exert its analgesic and antipyretic effects through the inhibition of prostaglandin synthesis within the central nervous system. Piroxicam, an oxicam derivative, acts as a non-selective inhibitor of the cyclooxygenase enzymes COX-1 and COX-2, thereby reducing the production of prostaglandins that mediate pain and inflammation both peripherally and centrally. In a Phase 3 clinical trial, the co-administration of these two agents was compared against monotherapy with each drug; the study concluded that the combination did not provide a statistically significant increase in analgesic efficacy over paracetamol alone for acute traumatic extremity pain.

Other names
paracetamol + nonsteroidal anti-inflammatory drugacetaminophen + piroxicamparacetamol + NSAID
02

Targets

CNR1 (Cannabinoid receptor 1)TRPV1 (Transient receptor potential cation channel subfamily V member 1)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on paracetamol + piroxicam.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on paracetamol + piroxicam.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call